Last Updated : April 18, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Zytiga (Resubmission) | Abiraterone | Prostate Cancer Resubmission | Withdrawn | |||
| Avodart | Dutasteride | Prostatic hyperplasia, benign | List in a similar manner to other drugs in class | Complete | ||
| Humira | Adalimumab | Psoriasis | List with clinical criteria and/or conditions | Complete | ||
| Stelara | Ustekinumab | Psoriasis | List with clinical criteria and/or conditions | Complete | ||
| Silkis | Calcitriol | Psoriasis, mild to moderate plaque | Do not list | Complete | ||
| Amevive | Alefacept | Psoriasis, moderate to severe chronic plaque | Do not list | Complete | ||
| Raptiva | Efalizumab | Psoriasis, moderate to severe chronic plaque | List with clinical criteria and/or conditions | Complete | ||
| Amevive | Alefacept | Psoriasis, moderate to severe chronic plaque | Do not list | Complete | ||
| Raptiva | Efalizumab | Psoriasis, moderate to severe chronic plaque | N/A | Complete | ||
| Tremfya | guselkumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 18, 2024